|
1
|
Yuan B, Zhang J and Zhang YQ: Research
progress of relation between GnRH and its receptor and tumors. Prog
Anatomical Sci. 8:367–371. 2002.(In Chinese).
|
|
2
|
Jia PY and Wang YX: Application of
gonadotropin-releasing hormone and its receptor in cancer therapy.
J Int Pharm Res. 36:179–183. 2009.(In Chinese).
|
|
3
|
Yin H, Cheng KW, Hwa HL, Peng C, Auersperg
N and Leung PC: Expression of the messenger RNA for
gonadotropin-releasing hormone and its receptor in human cancer
cell lines. Life Sci. 62:2015–2023. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wen S, Schwarz JR, Niculescu D, Dinu C,
Bauer CK, Hirdes W and Boehm U: Functional characterization of
genetically labeled gonadotropes. Endocrinology. 149:2701–2711.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xie J: The current development and
prospect of tumor molecular nuclear medicine. Kawakita medical
report. 24:315–318. 2009.(In Chinese).
|
|
6
|
Ji Q, Zhou J and Huang W:
Immunohistochemical and in situ hybridization study of thyroid
gonadotropin-releasing hormone receptor in rats. Chinese J
Histochem Cytochem. 11:241–243. 2002.(In Chinese).
|
|
7
|
Emons G, Ortmann O, Becker M, Irmer G,
Springer B, Laun R, Hölzel F, Schulz KD and Schally AV: High
affinity binding and direct antiproliferative effects of LHRH
analogues in human ovarian cancer cell lines. Cancer Res.
53:5439–5446. 1993.PubMed/NCBI
|
|
8
|
Schottelius M, Berger S, Poethko T,
Schwaiger M and Wester HJ: Development of novel 68Ga- and
18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
Bioconjug Chem. 19:1256–1268. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mankoff DA, Link JM, Linden HM,
Sundararajan L and Krohn KA: Tumor receptor imaging. J Nucl Med. 49
Suppl 2:149S–163S. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gründker C, Völker P and Emons G:
Antiproliferative signaling of luteinizing hormone-releasing
hormone in human endometrial and ovarian cancer cells through G
protein alpha(I)-mediated activation of phosphotyrosine
phosphatase. Endocrinology. 142:2369–2380. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gerber B, von Minckwitz G, Stehle H,
Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B,
Ortmann O, et al: Effect of luteinizing hormone-releasing hormone
agonist on ovarian function after modern adjuvant breast cancer
chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 29:2334–2341.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Emons G, Schröder B, Ortmann O, Westphalen
S, Schulz KD and Schally AV: High affinity binding and direct
antiproliferative effects of luteinizing hormone-releasing hormone
analogs in human endometrial cancer cell lines. J Clin Endocrinol
Metab. 77:1458–1464. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moreau JP, Delavault P and Blumberg J:
Luteinizing hormone-releasing hormone agonists in the treatment of
prostate cancer: a review of their discovery, development, and
place in therapy. Clin Ther. 28:1485–1508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rose A, Froment P, Perrot V, Quon MJ,
LeRoith D and Dupont J: The luteinizing hormone-releasing hormone
inhibits the anti-apoptotic activity of insulin-like growth
factor-1 in pituitary alphaT3 cells by protein kinase C
alpha-mediated negative regulation of Akt. J Biol Chem.
279:52500–52516. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Szende B, Srkalovic G, Schally AV, Lapis K
and Groot K: Inhibitory effects of analogs of luteinizing
hormone-releasing hormone and somatostatin on pancreatic cancers in
hamsters. Events that accompany tumor regression. Cancer.
65:2279–2290. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Greco F and Vicent MJ: Combination
therapy: opportunities and challenges for polymer-drug conjugates
as anticancer nanomedicines. Adv Drug Deliv Rev. 61:1203–1213.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Duncan R: Polymer conjugates as anticancer
nanomedicines. Nat Rev Cancer. 6:688–701. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eidne KA, Flanagan CA, Harris NS and
Millar RP: Gonadotropin-releasing hormone (GnRH)-binding sites in
human breast cancer cell lines and inhibitory effects of GnRH
antagonists. J Clin Endocrinol Metab. 64:425–432. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Barda Y, Cohen N, Lev V, Ben-Aroya N, Koch
Y, Mishani E, Fridkin M and Gilon C: Backbone metal cyclization:
novel 99mTc labeled GnRH analog as potential SPECT molecular
imaging agent in cancer. Nucl Med Biol. 31:921–933. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Seitz S, Buchholz S, Schally AV, Weber F,
Klinkhammer-Schalke M, Inwald EC, Perez R, Rick FG, Szalontay L,
Hohla F, et al: Triple negative breast cancers express receptors
for LHRH and are potential therapeutic targets for cytotoxic
LHRH-analogs, AEZS 108 and AEZS 125. BMC Cancer. 14:8472014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rusiecki JA, Holford TR, Zahm SH and Zheng
T: Breast cancer risk factors according to joint estrogen receptor
and progesterone receptor status. Cancer Detect Prev. 29:419–426.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Van Den Bossche B and Van de Wiele C:
Receptor imaging in oncology by means of nuclear medicine: current
status. J Clin Oncol. 22:3593–3607. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Imai A, Takagi A, Horibe S, Takagi H and
Tamaya T: Fas and Fas ligand system may mediate antiproliferative
activity of gonadotropin-releasing hormone receptor in endometrial
cancer cells. Int J Oncol. 13:97–100. 1998.PubMed/NCBI
|
|
24
|
Cai W and Chen X: Multimodality imaging of
vascular endothelial growth factor and vascular endothelial growth
factor receptor expression. Front Biosci. 12:4267–4279. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Virgolini I, Traub T, Novotny C, Leimer M,
Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, et
al: Experience with indium-111 and yttrium-90-labeled somatostatin
analogs. Curs Pharm Des. 8:1781–1807. 2002. View Article : Google Scholar
|
|
26
|
Meko JB, Doherty GM, Siegel BA and Norton
JA: Evaluation of somatostatin-receptor scintigraphy for detecting
neuroendocrine tumors. Surgery. 120:975–983. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Katsuno M, Adachi H, Doyu M, Minamiyama M,
Sang C, Kobayashi Y, Inukai A and Sobue G: Leuprorelin rescues
polyglutamine-dependent phenotypes in a transgenic mouse model of
spinal and bulbar muscular atrophy. Nat Med. 9:768–773. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Reisinger I, Bohuslavitzki KH, Brenner W,
Braune S, Dittrich I, Geide A, Kettner B, Otto HJ, Schmidt S and
Munz DL: Somatostatin receptor scintigraphy in small-cell lung
cancer: results of a multicenter study. J Nucl Med. 39:224–227.
1998.PubMed/NCBI
|
|
29
|
Thakur ML, Marcus CS, Saeed S, Pallela V,
Minami C, Diggles L, Le Pham H, Ahdoot R and Kalinowski EA:
99mTc-labeled vasoactive intestinal peptide analog for rapid
localization of tumors in humans. J Nucl Med. 41:107–110.
2000.PubMed/NCBI
|
|
30
|
Fekete M, Zalatnai A, Comaru-Schally AM
and Schally AV: Membrane receptors for peptides in experimental and
human pancreatic cancers. Pancreas. 4:521–528. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Szepeshazi K, Schally AV, Groot K and
Halmos G: Effect of bombesin, gastrin-releasing peptide
(GRP)(14–27) and bombesin/GRP receptor antagonist RC-3095 on growth
of nitrosamine-induced pancreatic cancers in hamsters. Int J
Cancer. 54:282–289. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peremans K, Cornelissen B, Van Den Bossche
B, Audenaert K and Van de Wiele C: A review of small animal imaging
planar and pinhole spect Gamma camera imaging. Vet Radiol
Ultrasound. 46:162–170. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Friess H, Berberat P, Schilling M, Kunz J,
Korc M and Büchler MW: Pancreatic cancer: the potential clinical
relevance of alterations in growth factors and their receptors. J
Mol Med (Berl). 74:35–42. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schottelius M, Berger S, Poethko T,
Schwaiger M and Wester HJ: Development of novel 68Ga- and
18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
Bioconjug Chem. 19:1256–1268. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Reubi JC and Maecke HR: Peptide-based
probes for cancer imaging. J Nucl Med. 49:1735–1738. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Medina RA and Owen GI: Glucose
transporters: expression, regulation and cancer. Biol Res. 35:9–26.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang R: Clinical outlook for
radio-immunity imaging. Int J Radiat Med Nucl Med Volume. 13:40–42.
1989.
|
|
38
|
Wang R, Zhang C, Yu L and Guo Y: Clinical
application of radioimmunoimaging with 99mTc-BDI-1 in the diagnosis
of bladder cancer. Chin Med J (Engl). 113:396–399. 2000.PubMed/NCBI
|
|
39
|
Vriesendorp HM and Vriesendorp FJ: A
review of the intravenous administration of radiolabeled
immunoglobulin G to cancer patients. High or low protein dose?
Cancer Biother Radiopharm. l8:35–46. 2003. View Article : Google Scholar
|
|
40
|
Kang JH and Chung JK: Molecular-genetic
imaging based on reporter gene expression. J Nucl Med. 49 Suppl
2:164S–179S. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cai W and Chen X: Multimodality molecular
imaging of tumor angiogenesis. J Nucl Med. 49 Suppl 2:113S–128S.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
de Jong M, Breeman WA, Bernard BF, Bakker
WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M,
Srinivasan A, et al: [177Lu-DOTA0,Tyr3]octreotate for somatostatin
receptor-targeted radionuclide therapy. Int J Cancer. 92:628–633.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Khan TS, Sundin A, Juhlin C, Långström B,
Bergström M and Eriksson B: 11C-metomidate PET imaging of
adrenocortical cancer. Eur J Nucl Med Mol Imaging. 30:403–410.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dietz DW, Dehdashti F, Grigsby PW, Malyapa
RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ and Siegel
BA: Tumor hypoxia detected by positron emission tomography with
60Cu-ATSM as a predictor of response and survival in patients
undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a
pilot study. Dis Colon Rectum. 51:1641–1648. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chao KS, Bosch WR, Mutic S, Lewis JS,
Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA and Welch
MJ: A novel approach to overcome hypoxic tumor resistance:
Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat
Oncol Biol Phys. 49:117l–1182. 2001. View Article : Google Scholar
|
|
46
|
Dehdashti F, Grigsby PW, Mintun MA, Lewis
JS, Siegel BA and Welch MJ: Assessing tumor hypoxia in cervical
cancer by positron emission tomography with 60Cu-ATSM: relationship
to therapeutic response-a preliminary report. Int J Radiat Oncol
Biol Phys. 55:1233–1238. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Suzuki T, Nakamura K, Kawase T and Kubo A:
Monitoring of response to radiation therapy for human tumor
xenografts using 99mTc-HL91
(4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime). Ann
Nucl Med. 17:131–138. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mochizuki T, Kuge Y, Zhao S, Tsukamoto E,
Hosokawa M, Strauss HW, Blankenberg FG, Tait JF and Tamaki N:
Detection of apoptotic tumor response in vivo after a single dose
of chemotherapy with 99mTc-Annexin V. J Nucl Med. 44:92–97.
2003.PubMed/NCBI
|
